Table 1.
Demographic characteristics and clinical features of the patients with prostate cancer
| Localized stage | Metastatic stage | ||||
|---|---|---|---|---|---|
| T2 | T3 | T4 | mHSPC | mCRPC | |
| (N*=11, n†=11) | (N = 9, n = 9) | (N = 6, n = 6) | (N = 10, n = 10) | (N = 23, n = 28) | |
| Age, median, IQR, years | 70 (55‐84) | 71 (62‐76) | 72 (59‐80) | 75 (64‐80) | 75 (57‐84) |
| PSA, median, IQR, ng/ml | 8.9 (4.2‐11.6) | 12.5 (8.3‐16.9) | 23.3 (14.5‐36.8) | 126.2 (85.2‐155.2) | 98.4 (30.6‐150.8) |
| Gleason score (%) | |||||
| 6 | 7 (63.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 7 | 2 (18.2) | 4 (44.5) | 1 (16.7) | 0 (0.0) | 2 (8.7) |
| 8 | 2 (18.2) | 1 (11.1) | 2 (33.3) | 5 (50.0) | 6 (26.1) |
| 9 | 0 (0.0) | 4 (44.4) | 3 (50) | 3 (30.0) | 11 (47.8) |
| 10 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (20.0) | 4 (17.4) |
| Node metastasis (%) | |||||
| Yes | 0 (0.0) | 0 (0.0) | 1 (16.7) | 6 (55.6) | 11 (4.3) |
| No | 11(100.0) | 9 (100.0) | 5 (83.3) | 4 (44.4) | 12 (4.3) |
| Visceral or bone metastasis (%) | |||||
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 10 (100.0) | 23 (100.0) |
| No | 11 (100.0) | 9 (100.0) | 6 (100.0) | 0 (0.0) | 0 (0.0) |
| Prior therapy (%) | |||||
| None | 11 (100.0) | 9 (100.0) | 6 (100.0) | 2 (20.0) | 0 (0.0) |
| Radiation | — | — | — | 1 (10.0) | 11 (39.2) |
| Taxane | — | — | — | 0 (0.0) | 5 (17.9) |
| Estramustine Phosphate | — | — | — | 0 (0.0) | 1 (3.5) |
| GnRH | — | — | — | 7 (70.0) | 4 (14.3)) |
| Antiandrogen | — | — | — | 0 (0.0) | 11 (39.2) |
| Abiraterone | — | — | — | 0 (0.0) | 2 (7.1) |
| Enzalutamide | — | — | — | 0 (0.0) | 5 (17.9) |
Abbreviations: GnRH, gonadotropin‐releasing hormone; mCRPC, metastatic castration‐resistant prostate cancer; mHSPC, metastatic hormone‐sensitive prostate cancer; N*, The number of patients; n†, The number of blood samples; PSA, prostate‐specific antigen.